UroGen Pharma Reports Second Quarter 2018 Financial Results and Recent Corporate Developments
August 14, 2018 07:00 ET
|
UroGen Pharma Ltd.
Plan to Initiate Q4 2018 Rolling New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (FDA) for UGN-101, Ahead of Initial Projection of Q1 2019 Initiated Phase 2b Clinical...
UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer
August 08, 2018 08:00 ET
|
UroGen Pharma Ltd.
Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to Prepare UroGen for its Transition from a Clinical Stage Company to Commercialization...
UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018
August 07, 2018 08:00 ET
|
UroGen Pharma Ltd.
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report second...
UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel™) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)
July 11, 2018 08:00 ET
|
UroGen Pharma Ltd.
Company Expects to Begin U.S. Phase 2b Clinical Trial in Q3 2018 UGN-102 Has Potential to Become the First Front Line Non-Surgical Therapy for Patients with LG NMIBC RA’ANANA, Israel and NEW YORK,...
UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors
July 10, 2018 08:00 ET
|
UroGen Pharma Ltd.
Tomasello is a Renowned Industry Expert Responsible for the Commercialization of Revolutionary, Multi-Billion Dollar Products in Hematology-Oncology RA’ANANA, Israel and NEW YORK, July 10, 2018 ...
UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award
June 13, 2018 08:00 ET
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, June 13, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance
June 05, 2018 08:00 ET
|
UroGen Pharma Ltd.
RA’ANANA, Israel, and NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference
May 29, 2018 08:00 ET
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field...
UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
May 21, 2018 13:40 ET
|
UroGen Pharma Ltd.
Interim Results Showed Complete Response (CR) Rate of 59 Percent in Patients with Low-Grade UTUC CRs to Date Remain Durable at Three, Six and Nine-Month Follow-Up RA’ANANA, Israel and NEW YORK, May ...
UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments
May 15, 2018 08:00 ET
|
UroGen Pharma Ltd.
Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association...